Increasing prevalence of infectious diseases is expected to propel growth of the global cell culture media for vaccine market
High prevalence of infectious diseases is expected to drive the market growth over the forecast period. According to the Centers for Disease Control and Prevention (CDC), in 2017, around 9,105 tuberculosis cases and around 42,743 cases of lyme disease were reported in the U.S. Also, according to the study conducted by University of Oxford, 2018, the measles cases are currently high in several European countries, where over 82,500 measles cases were registered in Europe in 2018. The number was thrice as compared in 2017, while 15 times in comparison with 2016.
Moreover, increasing number of vaccine clinical trial in the North America is expected to augment the market growth. For instance, in April, 2018, BiondVax Pharmaceuticals Ltd. enrolled participants in the U.S. for a Phase 2 clinical trial of the company’s universal flu vaccine candidate, M-001.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients